Article
ePT--the Electronic Newsletter of Pharmaceutical Technology
Pfizer Proceeds with Biotech Manufacturing Expansion in Sweden
Author(s):
Stockholm, Sweden (Dec. 15)-As part of a plan to expand its biotechnology production capacity, Pfizer, Inc. commissioned the construction company Skanska AB to build a plant in Strangnas, Sweden for manufacturing Pfizer's human growth hormone product "Genotropin" (somatropin [rDNA origin] for injection).
Stockholm, Sweden (Dec. 15)-As part of a plan to expand its biotechnology production capacity, Pfizer, Inc. (New York, NY, www.pfizer.com) commissioned the construction company Skanska AB (www.skanska.com) to build a plant in Strångnås, Sweden for manufacturing Pfizer’s human growth hormone product “Genotropin” (somatropin [rDNA origin] for injection).
The plant is part of a SEK 1.5 billion ($219 million) investment by Pfizer in the Swedish facility. In addition to building the plant, Skanska also will be responsible for installing process equipment. Skanska's contracts amount to roughly SEK 600 million ($87 million).
The project consists of a 5,000-m2 building that will be adjoined to an existing plant. Construction is underway and is expected to proceed for 30 months.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
